Cannabinoid receptor activation reduced organ damage from chemotherapy drugs in preclinical studies

CB2 receptor activation attenuated doxorubicin-induced cardiotoxicity by enhancing antioxidant defenses and reducing inflammation. In cisplatin-induced kidney injury, cannabinoids reduced tubular cell death and inflammatory infiltrates. The endocannabinoid system was identified as a polypharmacological target that could simultaneously combat cancer and protect organs from chemotherapy damage.

Narrative review synthesizing preclinical evidence on cannabinoid receptor agonists (JWH-133, beta-caryophyllene, and others) for mitigating chemotherapy-induced organ toxicity. Covers cardiotoxicity, nephrotoxicity, hepatotoxicity, and neurotoxicity from agents including doxorubicin, cisplatin, cyclophosphamide, and methotrexate.

Organ toxicity from chemotherapy is a major clinical problem that limits treatment effectiveness and patient quality of life. If cannabinoids can protect organs while cancer treatment continues, this could be a significant therapeutic advance.

This positions cannabinoids not as alternative cancer treatments but as supportive care agents that protect healthy tissue during conventional chemotherapy. This pragmatic framing could facilitate clinical acceptance and research.

Entirely based on preclinical data. Translational gaps between animal models and human physiology remain significant. Selective CB2 agonists with adequate safety profiles are not yet available for clinical use. No clinical trials of cannabinoids as chemoprotective agents have been completed.